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ABSTRACT
Collagen VI myopathies are genetic disorders caused by mutations in
collagen 6 A1, A2 and A3 genes, ranging from the severe Ullrich
congenital muscular dystrophy to the milder Bethlemmyopathy, which
is recapitulated by collagen-VI-null (Col6a1−/−) mice. Abnormalities in
mitochondria and autophagic pathway have been proposed as
pathogenic causes of collagen VI myopathies, but the link between
collagen VI defects and these metabolic circuits remains unknown. To
unravel the expression profiling perturbation in muscles with collagen
VI myopathies, we performed a deep RNA profiling in both Col6a1−/−
mice and patients with collagen VI pathology. The interactome map
identified common pathways suggesting a previously undetected
connection between circadian genes and collagen VI pathology.
Intriguingly, Bmal1−/− (also known as Arntl) mice, a well-characterized
model displaying arrhythmic circadian rhythms, showed profound
deregulation of the collagen VI pathway and of autophagy-related
genes.The involvement of circadian rhythms in collagenVImyopathies
is new and links autophagy and mitochondrial abnormalities. It also
opens newavenues for therapies of hereditarymyopathies tomodulate
the molecular clock or potential gene–environment interactions that
might modify muscle damage pathogenesis.
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INTRODUCTION
Collagen VI (ColVI) is a major component of the extracellular matrix
(ECM) crucial for muscle cell adhesion, stability and regeneration.
ColVI forms a microfibrillar network involved in maintaining tissue
integrity through a structural link between different components of
connective-tissue basement membranes and cells (Allamand et al.,
2011). ColVI is a heterotrimeric molecule composed of three α-
chains encoded by distinct genes (COL6A1, COL6A2 and COL6A3).
The threeα-chains first assemble in equimolar association into a triple
helical monomer, and successively form dimers and tetramers
stabilized by disulfide bonds. The secreted tetramers give rise to a
network of microfilaments that bridge the sarcolemma with the
extracellular connective tissue (Bonaldo et al., 1990). Mutations
occurring in the three ColVI genes cause two major disease
phenotypes: a mild form, Bethlem myopathy, and a severe form,
Ullrich congenital muscular dystrophy (UCMD) (Gualandi et al.,
2012). Three additional ColVI genes have recently been described,
COL6A4, COL6A5 and COL6A6, and code for the α4(VI), α5(VI)
and α6(VI) protein chains, respectively. However, only α6(VI) is
highly expressed in skeletal muscle, although not associated with
basement membranes (Tagliavini et al., 2014a) and none of these
additional ColVI genes are known as disease genes in humans.
ColVI myopathies are well-defined conditions, characterized by a
broad spectrum of clinical features, ranging from prenatal onset with
decreased fetal movements; hypotonia or torticollis, early-
childhood onset, characterized by delayed motor milestones,
muscle weakness and contractures; and adult onset (4th–6th
decade), characterized by proximal weakness and Achilles tendon
or long finger flexor contractures (De Visser et al., 2004). Owing to
the progressive nature of the condition, 75% of patients over age
50 years need assistance for outdoor mobility (Jöbsis et al., 1999).
The severe phenotypewith early onset, UCMD, is characterized by
severe muscle weakness, striking hyperlaxity of distal joints, and
proximal joint contractures. In contrast to Bethlemmyopathy, UCMD
is marked by an early loss of ambulation and a rapid disease
progression leading to early death caused by respiratory failure
(Maraldi et al., 2009). In addition, two other conditions have
been associated with ColVI myopathy: autosomal-dominant limb-
girdle muscular dystrophy (LGMD), and autosomal-recessive
myosclerosis myopathy (Merlini et al., 2008; Scacheri et al., 2002).
Recently, theCOL12A1 genehas been shown tobemutated in patients
with a Bethlem-myopathy-like phenotype (Hicks et al., 2014).
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Nevertheless, UCMD and Bethlem myopathy can be inherited
accordingly to both dominant and recessive models, and generally,
neither the type of mutation (missense, nonsense, splicing insertion
or deletion), nor the effect of the mutation on the protein structure or
function allows precise discrimination between two phenotypes
(Allamand et al., 2011; Maraldi et al., 2009; Bönnemann, 2011).
This suggests that the genetic background of patients might
influence the expression of the mutated genes, therefore impacting
on the resulting phenotype.
The Col6a1−/− mouse is a well studied animal model for ColVI
myopathies. These mice carry a targeted inactivation of the α1(VI)
chain and exhibit an early onset myopathic phenotype that strongly
resembles Bethlem myopathy (Bonaldo et al., 1998). Muscle fibers
of Col6a1−/− mice show loss of contractile strength and a number
of structural defects in the hind limb muscle and especially in the
diaphragm. Although the pathology associated with collagen VI
myopathy is nonspecific and variable, it has been widely
documented (Grumati et al., 2010; Urciuolo et al., 2013). Both
muscles from mice and patients have been found to show
mitochondrial dysfunction accompanied by ultrastructural
alterations, increased spontaneous apoptosis and abnormal
propensity of the permeability transition pore (PTP) to open
(Irwin et al., 2003; Bernardi and Bonaldo, 2008; Tagliavini et al.,
2014b).
Col6a1−/− mice and UCMD or Bethlem myopathy patients also
show defective autophagy (Grumati et al., 2011). This suggests a
mechanism of disease pathogenesis that might be in part due to
defective regulation of autophagy, which leads to accumulation of
abnormal mitochondria and sarcoplasmic reticulum. Moreover, in
Col6a1−/− mice, changes in metabolic proteins resulting in
decreased glycolysis and affecting the tricarboxylic acid (TCA)
cycle fluxes lead to a different fate of α-ketoglutarate triggering
lipotoxicity. The metabolic changes are associated with changes of
proteins involved in mechanotransduction at the myotendineous
junction, costameric or sarcomeric level, and in energy metabolism
(De Palma et al., 2013). Recently, a strong depletion of the α6(VI)
chain in skeletal muscle has been reported as potential biomarker of
ColVI myopathies (Tagliavini et al., 2014a). In spite of these recent
achievements, a full understanding of ColVI disease pathogenic
mechanisms remains unknown.
Gene expression profiling and RNA sequencing are powerful
tools to explore the transcriptional alterations in disease tissues
(Sánchez-Pla et al., 2012). It brought great advances in cancer
research and disclosed deregulated transcripts that are now being
considered as prognostic or therapeutic biomarkers of neoplastic
diseases (Sevov et al., 2012; Campo, 2013). Considering the
availability of novel therapeutic possibilities for rare muscle
disorders (Aartsma-Rus and Muntoni, 2013), finding prognostic
biomarkers for disease severity or drug response will be of great
benefit for patient care and treatment (Ferlini et al., 2013; Scotton
et al., 2014). In this work, we explored RNA profiling of Col6a1−/−
mice and Bethlem myopathy and UCMD patients to identify
transcriptional patterns correlating with disease state. Such patterns
can identify specific pathway alterations and pathophysiological
biomarkers. This unbiased approach revealed marked changes
in the expression of genes involved in the circadian rhythm
pathway. We further supported these findings by protein studies
performed both in mice and in patients. In addition, RNA and
protein studies in the Bmal1−/− (also known as Arntl) mice, a
known animal model of circadian rhythm disruption, showed
profound deregulation of Col6a6 as well as of the autophagy-
related genes such as p62/SQSTM1 and AMPK. Although it has
been previously reported that disruption of circadian rhythms are
linked to skeletal muscle remodeling, function, performance and
aging, the involvement of the molecular clock genes in hereditary
myopathy as ColVI disease is a new finding. These findings
highlight new potential target genes involved in muscle damage
possibly addressing new therapies.
RESULTS
Overall gene expression profile in Col6a1−/− muscles reveals
changes in genes associated with muscle function
Gene expression array profiles of wild-type (WT) and Col6a1−/−
mice were compared in three muscle types: diaphragm, tibialis
anterior and gastrocnemius. To determine genes with statistically
significant differential expression (P<0.05 in limma package) we
analyzed each muscle type (either separately and in pools) and
determined average expression change over all muscle types. The
degree of transcriptional deregulation was different among
Col6a1−/− muscles, with 11,170 differentially expressed genes in
tibialis anterior, 6790 in diaphragm and 3759 genes in
gastrocnemius. To further support the finding of different tissue
susceptibility to ColVI deficiency, we performed sample clustering
of expression profiles from each muscle type for Col6a1−/− and in
WT mice. The resulting dendrogram is shown in Fig. S1A. We
found that the expression profiles of Col6a1−/− and WT
gastrocnemius were clustered together and therefore similar.
Indeed this supports the existing knowledge about muscle
involvement in the Col6a1−/− mouse model, where gastrocnemius
is very mildly affected, whereas tibialis and even more diaphragm
are severely affected (De Palma et al., 2013). In contrast, diaphragm
and tibialis anterior Col6a1−/− muscles clustered together and were
clearly separate from their WT counterparts, suggesting that ColVI
deficiency severely and similarly affects these muscle types
(Fig. S1).
Expression of genes associated with muscle development and
function was altered in Col6a1−/− mice (Table S1). The identified
changes involved several different muscle biology circuits,
including structure, metabolism, transcription and regulation.
There was variability between tested muscle types. A total of 60%
(26 out of 44) of muscle-specific genes changed their expression in
an opposite direction in tibialis anterior versus diaphragm, 23%
in tibialis anterior versus gastrocnemius (7 out of 30) and 67% in
gastrocnemius versus diaphragm (12 of 18). Tibialis anterior
showed differential expression of myosin, troponin and
calsequestrin isoforms (predominantly cardiac and slow), and
upregulation of Pax3. In diaphragm and tibialis anterior, the
differentially expressed genes included almost all members of the
dystroglycan complex (dystrophin, dystrobrevin, dystroglycan 1,
syntrophin, α-, β-, γ-sarcoglycans) and several transcription factors
important for muscle-related processes, such as MyoD1, MyoG,
MYF6, NFATc2 and Pax7. Embryonic isoforms of myosin were
upregulated in the diaphragm. Pax7, a marker of satellite cell
number, which can be regarded as a sign of muscle regeneration,
was also upregulated. This muscle type variability in the
transcription profile is not surprising given that these three
muscles have different metabolic properties and different fiber
type composition (Bonaldo et al., 1998).
Gene ontology groups and key expression regulators
analyses show deregulation of the circadian rhythmic
process in Col6a1−/− mice
Among the differentially expressed genes between Col6a1−/− and
WT mice, 479 changed expression in the same direction in all
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tissues with P<0.05. We used Gene Set Enrichment analysis
(GSEA) to identify gene ontology groups enriched with such genes.
The top ten gene ontology groups are listed in Fig. S2. Identified
gene ontology groups were broad categories and, therefore, do not
specifically address any definite biological effects occurring in
Col6a1−/− mice. We also performed gene ontology analysis of 334
genes differentially expressed in the ‘pooled’ data from all three
muscle groups compared with ‘pooled’ WT muscles. This GSEA
identified the gene ontology groups shown in Fig. 1. One of the top
ten gene ontology groups was ‘rhythmic process’, which contains
genes regulating circadian rhythms, as well as known genes that are
regulated downstream of the molecular clock, such as DBP, and all
were downregulated in Col6a1−/− muscles.
To identify key regulators that change their activity in Col6a1−/−
muscles, we used sub-network enrichment analysis (SNEA) in
Pathway Studio. Our first SNEAwas performed using the list of genes
differentially expressed in one direction in all muscle types as an
input. Regulators identified by this approach are shown in Fig. 2.
Genes changing their expression in one direction in all muscle types
are primarily regulated by inflammatory cytokines and their receptors.
In good agreement with the gene ontology analysis, SNEA of the
‘pooled’dataset foundBMAL1 (ARNTL),CLOCK,PER1andPER3
regulators that belong to cellular circadian rhythm pathway (Fig. 2;
Table S2). We then explored the intersection between the two SNEA
analyses and found consistent results (Fig. 2; Table S2). Indeed, we
found that CLOCK, BMAL1, GFI1B, IL2, CD28, PIM3 and
inflammatory cytokines were differentially expressed genes that
were also identified as being key regulators in all three comparisons.
To validate the 46 key regulators selected by SNEA, we studied
the differential expression of these transcripts using TaqMan low-
density arrays (TLDA). By comparing the microarray experiment
data to those of the TLDA cards, we observed the same trend of fold
change in 37 out of 46 genes (80%) of the diaphragm and tibialis
anterior, whereas in the gastrocnemius we found 32 out of 46 genes
(70%) with these features (Fig. S3A,B).
Both in the diaphragm and tibialis anterior and, to a lesser extent
in gastrocnemius, the TLDA and microarray data for regulators of
the rhythmic process (BMAL1, ATF5, CLOCK, DBP, EGR1,
FKBP5, PER1, PER2 and PER3) and transcription factors
important for muscle-related processes (MyoD1, MyoG, MYF6,
PAX7) were in good agreement. This confirmed the deregulation of
these two pathways in the Col6a1−/− mice (Fig. S3B).
Fig. 1. Gene ontology groups that were
differentially represented in samples from pooled
tissues from three muscle tissues. Muscle types
examined were the diaphragm, gastrocnemius and
tibialis anterior, of four Col6a1−/− and WT mice. A
representation of the gene ontology groups for the 334
genes differentially expressed in the pooled data from
all three muscle groups (diaphragm, gastrocnemius
and tibialis anterior) of Col6a1−/− mice compared with
that in pooled wild-type muscles (A shows upregulated
genes, and B shows downregulated genes).
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Western blotting revealed that CLOCK levels were significantly
(Student’s t-test, n=3, P<0.05) increased in diaphragm and tibialis
anterior muscles of Col6a1−/− mice compared with their respective
WT controls, whereas they remained unchanged in gastrocnemius.
MAT2A protein levels did not change significantly in the
diaphragm, whereas in tibialis anterior and gastrocnemius muscles
they were, respectively, increased and decreased (Fig. 3A).
Abnormal collagen VI expression in Bmal1−/− mice, a model
for circadian rhythm deregulation
There are multiple genetic mouse models in which molecular
clock factors have been knocked out, but of these models only the
Bmal1−/− mice exhibit complete loss of behavioral rhythm under
normal housing conditions (Bunger et al., 2000). We adopted this
last model in order to have a homogeneous phenotype, with
complete failure of circadian control. Western blot analysis of
gastrocnemius muscles of Bmal1−/− mice revealed significant
changes in the levels of ColVI chains, with decreased α6(VI) and
increased α3(VI) levels. Interestingly, downregulation of COL6A6
was also recently observed by us in UCMD and Bethlem myopathy
muscles (Tagliavini et al., 2014a). In addition to ColVI, components
of the autophagy pathway were also affected in the muscle of
Bmal1−/− mice with increased LC3A (also known as MAP1LC3A)
and decreased p62 (also known as SQSTM1) levels, whereas Beclin
1 levels were unchanged.We also found an increase in the activation
status of AMPK, as defined by a higher phosphorylated AMPK to
total AMPK ratio; however, this was driven in part by a significant
decrease in the levels of total AMPK (Fig. 3B).
Circadian genes show deregulation in muscle from UCMD
and Bethlem myopathy patients
Gene expression profiles in three patients (one with UCMD and two
with Bethlem myopathy) were compared to healthy controls by
RNAseq, and we identified several altered transcripts, which we
grouped into gene ontology categories (Fig. 4A). Genes that were
deregulated in muscles from UCMD and Bethlem myopathy
patients are reported in Table 1. In all three patients, we identified
seven consistently upregulated genes belonging to transcription
factor, metabolism process and cellular stress response categories.
The 24 consistently downregulated genes were involved in
signaling, metabolism, immunity and cell adhesion, axon
guidance and circadian rhythm, including DNA repair gene
ontology categories (Fig. 4B). Consistent with a link to circadian
rhythms, we found that eight of the genes listed in Table 1 are
known to be circadian in mouse skeletal muscle and/or changed in
expression in the Bmal1−/− mouse.
In order to find gene ontology groups deregulated in different
samples,we performedGSEAanalysis (P-value 0.05 cut-off) for each
patient separately. Bi-clustering was performed by using the Jaccard-
based distance betweengeneontologygroups (based on the numberof
common genes in groups). This method allowed finding of common
deregulated ‘patterns’ in different patients, even though the GSEA
method shows different gene ontology groups. We found genes
coding proteins belonging to postsynaptic membrane, cell junction
and synapse, regulation of ion transmembrane transport, protein
homo-oligomerization or protein-specific binding, cell-surface-
receptor-linked signaling pathways and DNA repair or response to
DNA damage, including circadian rhythm genes (Fig. 4A,B).
Considering the evidence from both mice and human studies for
the deregulation of circadian genes inmuscles with ColVI defects, we
performed an real-time PCR expression analysis of CLOCK and
MAT2A genes in another 11 UCMD and 12 Bethlem myopathy
patients. We found that the CLOCK gene was significantly
downregulated (P<0.0001) in all UCMD muscles. The MAT2A
transcript showed a milder downregulation, although not statistically
significant (P=0.0753), but only in UCMD patients (Fig. 3C).
Bethlemmyopathy patients did not show any significant deregulation
in the analyzed circadian genes. Western blotting in four UCMD and
three Bethlem myopathy patient muscles showed significantly
increased CLOCK protein levels (P<0.05, ANOVA plus Tukey,
n=3) in UCMD patients only, whereas MAT2A protein levels were
increased in Bethlem myopathy patients only (Fig. 3D).
DISCUSSION
ColVI myopathies have been both clinically and genetically
defined, and alterations in the apoptosis and autophagy circuits
have been reported. Nevertheless, the link between mutations of
COL6A1–COL6A3 genes and the muscle dysfunction seen in ColVI
myopathy still remains elusive.We therefore adopted RNA profiling
to study muscle from both Col6a1−/− mice and Bethlem myopathy
Fig. 2. Regulators identified by SNEA upstream genes that are differentially expressed between Col6a1−/− and wild-type mice muscle tissues. Genes
with P<0.05 are shown. Blue highlighting represents SNEA-derived regulators identified from differentially expressed genes in samples pooled from three muscle
types – diaphragm, gastrocnemius and tibialis anterior – from four Col6a1−/− in respect to WT mice. Yellow highlighting indicates SNEA-derived regulators
identified from differentially expressed genes that have the same direction of change in all muscle types. Green highlighting represents SNEA-derived regulators
with the same direction of change using both pooled and individual muscle approaches.
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or UCMD patient biopsies, searching for unique transcriptional
patterns. The idea was to detect specific signatures that might
enhance our understanding of the pathogenesis of ColVI
myopathies. In order to strengthen our findings, we also evaluated
protein expression of the transcripts that we found to be consistently
deregulated in both mouse and patient muscle tissue.
Col6a1−/− and Bmal1−/− mice shows connection between
ColVI myopathy and circadian genes
To our knowledge, this is the first attempt to study Col6a1−/− mice
by RNA profiling. Proteomic studies were performed by Irwin et al.
(2003) in Col6a1−/− mice, revealing the diaphragm as the most
severely affected muscle, having a deeply subverted ultrastructure
and evident loss of contractile strength, accompanied by changes in
proteins involved in mechanotransduction. Our pooled data
identified 334 differentially expressed genes in Col6a1−/− versus
WT, showing consistent deregulation of the genes involved in
metabolic processes and regulation of transcription, known to be
affected in myopathies, as well as in those of the circadian CLOCK
gene. This is an entirely new observation.
We show major transcriptional changes in the diaphragm
and tibialis anterior, accordingly to the proteomic findings
(De Palma et al., 2013). All muscles shared similar alterations in
genes involved in the inflammatory response, cell proliferation,
Fig. 3. Transcription of circadian genes and expression analysis onmice and humanmuscles. (A)Western blotting of CLOCK andMAT2A in three different
muscle tissues (diaphragm, gastrocnemius and tibialis anterior) of five 6-month-old male Col6a1−/− and wild-type (Ctrl) mice revealed a significant upregulation
(*P<0.05, t-test) of CLOCK protein levels in the diaphragm and tibialis anterior, whereas the MAT2a protein level was significantly altered in tibialis anterior and
gastrocnemius, which showed an increase and decrease, respectively. (B) Immunoblotting to evaluate the protein levels of p62, α3(VI), α6(VI), α1(VI), Beclin 1,
LC3, phosphorylated AMPK (p/AMPK), AMPK and α-tubulin in the gastrocnemius muscle of four male 30–35-week-old wild-type (Ctrl) and Bmal1−/−mice. The
analysis identified a downregulation of α6(VI), and upregulation of α3(VI). Components of autophagic pathway were also affected, expressed as an increase in
LC3 (LC3A) and decrease in p62. (C) Real-time analysis of CLOCK gene (black bars) and MAT2A gene (white bars) transcription in the cohort of 12 Bethlem
myopathy and 12 UCMD patients. The analysis identified a significant deregulation of the CLOCK gene compared to controls (Ctrl) in the UCMD patients
only (**P<0.0001, t-test). All the experiments were performed in triplicate [CLOCK analysis, UCMD: 0.4137±0.2146; Bethlem myopathy (BM): 0.9709±0.5846;
MAT2A analysis, UCMD: 0.7599±0.4012; Bethlem myopathy (BM): 1.1918±0.5074; mean±s.d.]. (D) Western blotting of CLOCK and MAT2A in four Bethlem
myopathy, eight UCMD patients, and 30 patients affected by other diseases (BMD and DMD), as well as five healthy controls (Ctrl), showed a significant increase
(*P<0.05, ANOVA) in CLOCK protein levels in UCMD patients only; MAT2A was slightly but significantly increased in Bethlem myopathy patients.
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transcriptional regulation and metabolism, but differed substantially
in the direction of expression change in a number of genes related to
muscle functions, including transcription, metabolism, structure
and regulation – a not entirely unexpected finding considering that
these three muscles have different morphogenetic origins and
functional requirements (Eberhard and Jockusch, 2004; Merrell and
Kardon, 2013).
The CLOCK gene deregulation, we also confirmed at the protein
level in Col6a1−/− mice, suggests a previously unreported
relationship between circadian rhythms, the molecular clock and
myopathy. The Col6a1−/− model shows both muscle and
osteotendinous junction damage (Izu et al., 2011, 2012), reflecting
defective costamerogenesis and altered mechanotransduction
(De Palma et al., 2013). Specific activation of both myocardin-
related transcription factors (MRTFs) and ternary complex factors
(TCFs), whose targets are regulators of cytoskeleton dynamics and
mechanosensing, have potential to reset the molecular clock through
regulation of PER1, PER2, BMAL1 and other CLOCK genes
(Esnault et al., 2014). This first demonstration of a link between the
ECM and the profound alterations we detected in the circadian
rhythm or molecular clock pathway (BMAL1, ATF5, CLOCK,
DBP, EGR1, FKBP5, PER1, PER2 and PER3 genes) supports the
known data demonstrating that physical activity can regulate
circadian gene expression in skeletal muscle (Wolff and Esser,
2012). In addition, providing a further bridge between protein and
RNA data, intersection between the individual muscle groups and
the pooled transcription data, to identify key regulators, showed that
inflammatory cytokines and their receptors, known to be regulated
by PER1–PER3 genes, are significantly underexpressed. The
connection between ColVI and circadian genes is also strongly
supported by our protein findings in Bmal1−/− mice, which exhibit
significant changes in the levels of ColVI chains as well as
alterations of the autophagy pathway (Fig. 3B). Given that our
expression analyses were only performed at one time point, our
Fig. 4. Gene ontology groups that were differentially represented in ColVI patients as determined by RNAseq output. (A) Representation of the
differentially expressed genes in the indicated gene ontology (GO) groups in the ColVI patients (UCMD, severe Bethlem myopathy and Bethlem myopathy)
compared to control. (B) Venn diagrams showing the number of genes, identified by RNAseq analysis, constantly deregulated in the ColVI patients. The patients
shared an upregulation of genes involved in postsynaptic membrane, cell junction and synapse pathways, and a downregulation of genes belonging to response
to DNA damage stimuli and DNA repair pathways.
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results can only allow us to conclude that molecular clock pathway is
disrupted. Further studies are needed to determinewhether the clock
factors are phase shifted, damped or arrhythmic.
RNAprofiling of ColVI patients shows that there is a profound
deregulation in ECM-mediated structural muscle remodeling
and circadian genes
In the three ColVI patients (Bethlem myopathy, severe Bethlem
myopathy and UCMD) studied, the highly efficient RNAseq
analysis revealed many changes in transcription profile, as
expected for this progressive, chronic and severe myopathy. The
major changes observed, shared by all patients, were
underexpression or overexpression in proteins related to
membrane, cell junction or synapse, ion transmembrane transport,
protein homo-oligomerization or protein-specific binding, the cell-
surface-receptor-linked signaling pathway and circadian gene
pathways (Fig. 4B). The overexpressed genes we detected
(ZNF384, ZNF526, SCP2, SUOX, KIF1B, PCSK6 and SESN1)
are all involved in the control of gene expression and metabolic
pathways. As reported in UCMD muscles (Paco et al., 2013),
increased expression of these transcripts is associated with muscle
regeneration defects and inflammatory signatures. Our RNAseq data
confirm that this myopathy is associated with structural alterations
coupled with either signaling or regeneration failure (Bönnemann,
2011). The 24 downregulated genes we identified mainly involved
transcripts associated with cell–cell communication or adhesion,
and signaling. Deregulation of transcription, homeostasis and the
cell response was also evident. This RNAseq data combines with
that obtained by Paco et al. (2013) using array technology to indicate
that ColVI deficiency drives both structural remodeling of muscle
tissue, mediated by the ECM, adhesion, cell signaling and
metabolism genes, and a massive immune response. The central
role of metabolism in muscle remodeling has also been confirmed
by De Palma et al. (2014), who described changes in the unfolded
protein response coupled with metabolic dysregulation, autophagic
impairment and mechanotransduction signaling alterations.
Most intriguingly, and in line with the mouse data, our RNAseq
analysis also revealed that circadian-related CRY2 and MAT2A
genes were profoundly deregulated. CRY2 is a well-established
negative regulator of the molecular clock mechanism that underlies
circadian rhythms, and MAT2A has a link with circadian rhythms
through regulation of the enzyme required for melatonin synthesis,
and mediates photoneural-circadian regulation of the pineal gland
(Kim et al., 2005). Using array technology, Paco et al. (2013) also
identified significant deregulation of the CLOCK pathway gene
EGR1, which also supports circadian rhythm involvement in the
pathogenesis of ColVI in both mice and patients. This finding
prompted us to profile both MAT2A and CLOCK in larger patient
cohorts, and the CLOCK gene was significantly downregulated
(P<0.0001) in all UCMD patients, the more severe form of ColVI
myopathy. All these data support that circadian genes, and CLOCK
in particular, have a role in ColVI myopathy pathogenesis.
Circadian genes and hereditary myopathies – a new
perspective
Circadian rhythms are approximate 24-h oscillations in physiology
and behavior driven by the molecular clock, a transcription–
translation feedback mechanism. A link between circadian genes
and skeletal muscle has been identified in both animal models and
in humans (Schroder and Esser, 2013). In particular, expression
profiling has identified genes expressed in a circadian manner in the
gastrocnemius, soleus and tibialis anterior muscles of mice
(McCarthy et al., 2007; Dyar et al., 2013; Hodge et al., 2015).
Analysis of human muscle samples taken 12 h apart have also
shown changes in clock gene expression, consistent with the
findings in mice (Zambon et al., 2003). Indeed, Zhang et al. (2012)
found that the molecular clock factors BMAL1 and CLOCK
transcriptionally regulate expression of MyoD1 in adult muscle,
thereby suggesting a link between the daily clock cycle and periods
of muscle repair and maintenance. We add to this growing body of
evidence by demonstrating, by RNA and protein analysis, a new
link between ColVI myopathy and deregulation of CLOCK
circadian gene expression in both mouse and human tissues.
In mice, the protein data fully support the transcription results.
Altered expression of CLOCK seems to be a marker of ColVI
disease severity, being upregulated in the most profoundly affected
muscles (tibialis anterior and diaphragm). In this way, CLOCK
involvement appears to provide the missing link between
autophagic pathway alterations and the physiopathogenesis of
ColVI myopathies (Fig. 5). Supporting this link, many
mitochondrial genes show a circadian oscillation in expression
and are significantly downregulated in the muscle of the CLOCK
mutant mice (McCarthy et al., 2007); in addition, the circadian
animal models (both ClockΔ19 and Bmal1−/−) have a dramatic
reduction (40% less) in the mitochondrial volume. In these mutant
mice, the remaining mitochondria display a pathological
morphology characterized by swelling and disruption of cristae,
associated with an increased uncoupling of respiration (Andrews
et al., 2010). These findings suggest that circadian genes can
modulate the respiratory defects. Unsurprisingly, therefore, protein
analysis in the Bmal1−/−mice identified a reduced expression of the
α6(VI) chain. Interestingly, a severe depletion of the α6(VI) chain
has recently been identified both in skeletal muscle and muscle cell
cultures of ColVI patients, and this protein change has been
proposed as a diagnostic marker of ColVI diseases (Tagliavini et al.,
2014a). Indeed, timing plays a crucial role in muscle remodeling.
For instance, Dadgar et al. (2014) demonstrated that asynchrony
drives fibrosis and regeneration failure in the mdx model, finding a
link between profound deregulation of global muscle transcription
and the muscle damage seen in various dystrophies, including
dystrophinopathies and several LGMD types. In addition, BMAL1
has recently been found to be involved in myogenic response to
muscle damage, orchestrating the regeneration processes in adult
skeletal muscle (Chatterjee et al., 2015).
Although these studies suggest that the circadian circuit plays a
crucial role in muscle function and regeneration, the mechanism
mediating these effects in skeletal-muscle-wasting diseases remains
to be elucidated. In summary, our results demonstrate, for the first
time, a deregulation of circadian genes in skeletal muscle of ColVI
myopathy that might lead to characterizing the involvement of
circadian clock circuit in many other muscle-wasting diseases,
opening new therapeutical perspectives.
Putative models linking collagen VI myopathies with
circadian rhythm deregulation
The new data suggest a pathogenic connection between circadian
rhythm gene deregulation and collagen-VI-related myopathies. It
appears that CLOCK gene deregulation could provide a link
between autophagy, mitochondrial abnormalities and ColVI
diseases. In light of the asynchrony recently described as the
mechanism driving regeneration failure (Dadgar et al., 2014), this
relationship could be expressed as one of the two following
scenarios. First, that circadian rhythm deregulation is a downstream
effect of ColVI deficiency and contributes to muscle damage
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pathogenesis (Fig. 6A). In this hypothesis, the crucial player
interconnecting ColVI deficiency with circadian rhythm could be
the inappropriate persistence of AKT1 activation. Owing to the
reduced ColVI expression, this would lead not only to the
downregulation of autophagy (Grumati and Bonaldo, 2012), but
also to the activation of the HIF1A transcription factor and the
consequent downregulation of GSK3-β kinase. Indeed, muscle
regeneration is a finely regulated process which drives the
transcription of myogenic factors through the orchestration of cell
contact, growth factors and various hormones. Murine models
lacking or constitutively expressing AKT genes show severe muscle
deficiency or extensive hypertrophy, respectively (Wilson and
Rotwein, 2007; Peng et al., 2003; Lai et al., 2004), implicating AKT
genes (AKT1 and AKT2) in both the development and regeneration
of muscle. Serra et al. (2007) hypothesize that this might arise
through convergence of the AKT pathway and the p38 MAPK
circuit at the chromatin level controlling the assembly of myogenic
transcriptome and driving the regeneration process.
The second scenario is that circadian rhythm deregulation in
ColVI myopathies is an independent event acting as a secondary
modifier of disease severity (Fig. 6B). Our observation that the
collagen VI α6 chain is downregulated in a mouse circadian
model could suggest that circadian genes are genetic modifiers able
to influence the primary ColVI defect. It is well recognized that
the molecular clock in skeletal muscle can be modified by
environmental factors including time of feeding or time of
physical activity (Wolff and Esser, 2012; Hatori and Panda,
2015). Merging this concept with the known direct control that
circadian genes have on MyoD1 (muscle development), PGC1
(mitochondria) and ATG14 (autophagy circuit) proteins provides
the model through which circadian rhythm disruption could
function independently to modify disease severity. It might
therefore be enlightening to explore circadian genes in the many
ColVI patients whose causative mutations are still unknown
(recently mutations in COL12A1 gene have been linked to the
UCMD and Bethlem myopathy phenotype) (Hicks et al., 2014).
In conclusion, our demonstration of circadian gene involvement
in the pathogenesis of ColVI myopathy in both an animal model
and human patients opens new avenues for both pathogenesis
and treatment of hereditary muscle diseases. Timing and
synchronization might have different effects on gene expression,
depending on the specific gene mutation (COL6 or DMD).
Different key regulators, such as AKT1 for COL6 myopathies and
TGFB1 for dystrophin mutations (Dadgar et al., 2014), might be
implicated, as these two muscle diseases have different pathogenic
signatures, represented by defective autophagy and massive muscle
necrosis, respectively. Finally, given that CLOCK is downregulated
only in the severe UCMD phenotype, it should be further explored
as a severity biomarker in patients with myopathies characterized by
a severe muscle remodeling, with a view to applications in
both disease stratification in patients and monitoring in clinical
trials.
Fig. 5. Interactome pathway linking ColVI and circadian rhythms. This model is based on the literature data analyzed by Pathway Studio, and shows the
connections between autophagy and circadian pathways. In this model the proposed pathophysiological mechanism of UCMD is that mTOR kinase activation
caused by ColVI deficiency yields not only downregulation of autophagy but also activation of the HIF1A transcription factor, which in turn represses the
expression of autophagy components through FoxO3 inhibition. In addition, HIF1A physically interacts with several major components of the circadian rhythm
pathway, bringing about a reduction of MyoD1 levels. AKT1 directly inhibits GSK3-β by phosphorylation. GSK3-β is a central negative regulator of circadian rhythm
that phosphorylates its components. GSK3-β repression by AKT1 further derepresses HIF1A, which is under GSK3-β negative control.
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MATERIALS AND METHODS
Analysis of Col6a1−/−mice
RNA extraction
For the focus of this work, we used standardized timing of muscle tissue
collection from the Col6a1−/− mice and the Bmal1−/− mice. Mice in all
colonies were maintained in normal 12-h-light–12-h-dark schedules with
lights on at 7 am (Zeitgeber time – ZT0). Muscle tissues were collected
between 10 am and 12 pm (ZT3–5) and frozen immediately in liquid N2. By
following these strict time of collection procedures this allows comparisons
across tissues and between animals. BothWT andCol6a1−/−mice belong to
C57BL/6 strain regarding the fiber type composition of different muscles as
previously described (Augusto et al., 2004).
Total RNA was isolated from three muscles (diaphragm, gastrocnemius
and tibialis) of male mice. Mice were wild type (four) and knock out (four),
at an age of 6 months. TRIzol extraction (Invitrogen), as specified by the
manufacturer, was used. RNA from each muscle was quantified with
Nanodrop (Thermo Scientific) spectrophotometer. Its integrity was
evaluated with a 2100 Bioanalyzer (Agilent) prior to pooling equal
amounts of RNA from muscles of the same kind.
Analysis of whole genome expression microarray data
We used the whole mouse genome gene expression kit including four arrays
of 44,000 probes (Agilent Technologies, G4122F) to measure the
transcriptional profile of muscle tissue samples of four mice. Sample
labeling and hybridization were performed in triplicate according to
protocols provided by Agilent (One-Color Microarray-Based Gene
Expression Analysis version 5.0.1). The hybridized array was processed by
Agilent scanner and Feature Extraction software (v9.5). The uniformness of
array hybridization was verified throughAgilent Quality Controls (Spike-in),
consisting of amixture of ten in-vitro-synthesized, polyadenylated transcripts
derived from theAdenovirusE1Agene, premixed at concentrations spanning
six logs and differing by one-log or half-log increments.
Microarray data analysis
Agilent’s Feature Extraction Software (v9.5) was used for array image
processing. Intensity data with local background adjustment by spatial
detrending were log-transformed and quantile-normalized. Synonymous
probes from the same gene were averaged. The software selected 28,052
probes for further analysis. To perform multi-way comparisons we utilized
the limma package (Smyth et al., 2005). This package fits a separate linear
model for each gene and uses moderated t-statistics to estimate differences
between arrays. Empirical Bayes analysis is used to improve statistical
power in small sample sizes. P-values were corrected for multiple testing
using the Benjamini and Hochberg correction (Benjamini and Hochberg,
1995).
To ascribe biological changes in knockout versus WT muscles we used
Gene Ontology term enrichment analysis. Gene ontology terms enriched in
the differentially expressed genes were identified using Fisher exact test. We
also performed Gene Set Enrichment Analysis (GSEA) (Subramanian et al.,
2005) using Pathway Studio 9 from Elsevier.
Potential transcription regulators of the observed expression changes
were identified using sub-network enrichment analysis (Sivachenko et al.,
2007) with default parameters implemented in Pathway Studio. This
algorithm identifies sub-networks consisting of a single expression regulator
Fig. 6. Proposed models that potentially link collagen VI myopathy and circadian genes. Model A suggests that circadian rhythm deregulation is a
downstream effect of ColVI deficiency and contributes to muscle damage pathogenesis. The inappropriate persistence of AKT1 activation could follow reduced
ColVI expression, leading not only to the downregulation of autophagy (also related to mTOR overexpression) but also to the activation of HIF1A transcription
factor and the downregulation of the GSK3-β kinase. HIF1A physically interacts with several central components of the circadian rhythm pathway: BMAL1 protein
(Hogenesch et al., 1998), PER1 (Chilov et al., 2001), PER2 (Koyanagi et al., 2003) and ROR-α. HIF1A activation has been shown to increase levels of PER1 and
CLOCK proteins (Chilov et al., 2001). Increased levels of PER1, a negative regulator of circadian rhythm, might lead to decreased transcriptional activity of the
BMAL1–CLOCK heterodimer, thereby slowing down circadian oscillations. GSK3-β also plays a role in the post-translational regulation of molecular clock
components, targeting BMAL1 for degradation at the end of the circadian cycle and stabilizing Rev-ErbA, a negative regulator of BMAL1 transcription (Pritchett
et al., 2012). Model B suggests that circadian rhythm deregulation in collagen VI myopathies is an independent event acting as a secondary modifier of disease
severity. The collagen VI α6 chain is downregulated in the mouse circadian model, suggesting that circadian genes can influence the primary ColVI defect, as
supported by the direct control circadian genes have on MyoD1 (muscle development) and ATG14 (autophagy circuit) proteins. Downregulation of CLOCK
induces ATG14 persistence and autophagy activation, whereas MyoD1 overexpression alters regeneration and induces muscle damage.
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(for example, transcription factor) and its downstream genes showing
concordant changes in expression between two conditions. Information
about gene–gene regulations is extracted from the literature using natural
language processing and stored in the Pathway Studio database. At the time
of analysis, the database contained over 250,000 expression relationships
between proteins. Relationships were extracted by natural language
processing of more than 22 million PubMed abstracts and 880,000 full-
text articles.
Microarray data analysis validation by fluidic cards
A total of 46 genes were selected for fluidic card analysis based on both
differential expression between wild-type and knockout mice and literature
analysis in Pathway Studio to find genes associated with the circadian
rhythm pathway, muscle regeneration, autophagy and apoptosis. Selected
genes were used to set up a custom TaqMan low density array (TLDA or
fluidic card) according to manufacturer specifications in order to validate
results obtained using the microarray platform. The major intrinsic protein
of lens fiber (MIP) gene was selected as negative control for its absence of
expression in the microarray data. Single fluidic card can analyze 48 genes
(47 test and the 18S control housekeeping gene) simultaneously in eight
samples and was run five times for each sample, it also included major
autophagic effector protein Beclin 1 (Grumati et al., 2010).
150 ng for each RNA pool was retrotranscribed using High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems), according to the
manufacturer’s instructions and loaded in a single port of the TLDA run on
ABI 7900HT System (Applied Biosystems) for 2 min at 50°C, 10 min at
95°C, followed by 40 cycles for 15 s at 97°C and 1 min at 60°C.Data analysis
was performed following the ΔΔCT Method (Applied Biosystems User
Bulletin #2) and using the 18S gene as calibrator and the WT samples as
controls with respect to the knockout samples. Calculated mean 2−ΔΔCT
values were log transformed and compared with normalized fold change
microarray data.
Western blotting and RNA analysis in Bmal1−/− mice
Immunoblotting was used to evaluate the protein levels of LC3A (rabbit
polyclonal, Thermo Scientific, PA1-16930; 1:1000), BECLIN1 (D40C5
rabbit mAb, Cell Signaling Technology, 3495; 1:1000), p62/SQSTM1
(Guinea pig polyclonal, Progen GP62-C; 1:1000), AMPK (rabbit
polyclonal, Cell Signaling Technology, 2532; 1:1000), phosphorylated
AMPK (rabbit polyclonal, Cell Signaling Technology, 2531; 1:1000),
COL6A1 (COL6A1 H-200, Santa Cruz Biotechnology, sc-20649, 1:1000),
COL6A3 and COL6A6 [rabbit polyclonal antisera against mouse a3(VI)
and a6(VI) were kindly supplied by R. Wagener, Cologne, Germany].
Gastrocnemius muscles from 30–35-week-old male wild-type and Bmal1−/−
(Andrews et al., 2010; Bunger et al., 2000) mice (both n=4) were
homogenized using extraction buffer (2% SDS, 10% glycerol, 2%
2-mercaptoethanol, 50 mM Tris-HCl, pH 8.8). The homogenized
samples were immediately incubated at 80°C for 5 min and protein
concentration was measured using a Bio-Rad DC protein assay kit. The
protein samples (50 µg/lane) were then subjected to 7.5% (for ColVI) or
10% SDS-PAGE. After electrophoresis, proteins were transferred to PVDF
membrane (Millipore). The membrane was blocked in Odyssey blocking
buffer (LI-COR) for 1 h and then incubated with primary antibody in 50%
Odyssey blocking buffer (LI-COR) diluted with 1× PBS containing 0.1%
Tween 20 for 1 h. The membrane was then washed and incubated with
horseradish peroxidase (HRP)-conjugated secondary Ab (for all collagen
VI proteins and p62) or Alexa-Fluor-680-conjugated secondary antibody
diluted in in 50% Odyssey blocking buffer (LI-COR). The protein signal
was detected either by incubation with ECL substrate and developing
signals by exposing the membrane to CL-Xposure film (for HRP-
conjugated secondary antibody), or by using the Odyssey infrared imager
(LI-COR, for Alexa Fluor 680 antibody). The protein bands were analyzed
by using ImageJ. The plots in the figures are average of four samples for
both wild type and Bmal1−/−. For the Bmal1−/− studies, the animal
procedures were conducted in accordance with institutional guidelines for
the care and use of laboratory animals as approved by the AAALAC
accredited, University of Kentucky Institutional Animal Care and Use
Committees with the protocol number: 00728M2004.
Analysis of Bethlem myopathy and UCMD patients
RNA extraction
The three ColVI patients have the following mutations: UCMD patient,
heterozygous c.819_833del p.Pro274_Gly278del in COL6A1 gene; severe
Bethlem myopathy patient: homozygous c.1393C>T p.Arg465* in
COL6A3 gene; Bethlem myopathy patient, heterozygous c.428+1G>A
p. Tyr122_Gly143del in COL6A1 gene. We obtained muscle biopsies from
ColVI patients after informed consent and approval of the Ethics Committee
of the University of Ferrara (no. 02/2009, 26 February 2009). The research
involving human subjects was performed according to the Helsinki
Declaration.
Muscle biopsy procedures were taken at a time according to the local
clinic rules, ranging from 8–10 am (central Europe time) or 10–12 am
(Greenwich time), depending on the sites. Fresh biopsies were frozen
following routine procedures. Because of the similarity in time of collection,
comparison of molecular clock components across patient samples can be
made. The muscle fiber composition in these three muscles shows a
predominance of fiber type I (Fig. S4). Generally, hereditary myopathies,
including the collagen VI myopathies, are characterized by the fiber type
disproportion with type I fiber hypotrophy and predominance (Schessl et al.,
2008).
Total RNA was isolated from skeletal muscle biopsies of three patients
with different phenotypes: UCMD, dominant and recessive Bethlem
myopathy and from one healthy control biopsy using the RNeasy-kit
(Qiagen, Chatsworth, CA) according to the manufacturer’s instructions. We
verified high-quality of isolated RNA and RNA integrity using an Agilent
Technologies 2100 Bioanalyzer. The isolated RNA had an RNA Integrity
Number (RIN) value of greater than 8.
RNAseq
1 μg of total RNA sample was used for poly(A)+ mRNA selection using
streptavidin-coated magnetic beads, followed by thermal mRNA
fragmentation. Fragmented mRNA was retro-transcribed using reverse
transcriptase (Super-Script II) and random primers. The cDNA was
converted into double-stranded cDNA, its ends were repaired using
Klenow fragment, T4 polynucleotide kinase and T4 polymerase, and then
cDNA was ligated to Illumina paired end adaptors. Size selection was
performed using a 2% agarose gel, generating cDNA libraries ranging in
size from 200 to 250 bp. Finally, the libraries were enriched using 15 cycles
of PCR (30 s at 98°C; 15 cycles of 10 s at 98°C, 30 s at 65°C, and 30 s at
72°C; then 5 min at 72°C) and purified by the QIAquick PCR purification
kit (Qiagen). The enriched libraries were diluted with elution buffer to a
final concentration of 10 nM. Each library was run at a concentration of
7 pM on one Genome Analyzer (GAIIe) lane using paired-end 100-bp
sequencing.
We performed mapping of reads to human genome using TopHat
software. TopHat, the splice junction mapper for RNASeq reads, was run
with default parameters. Supplied annotations from hg19 Refseq refGene
were downloaded from the UCSC Genome Browser. The mapping results
from TopHat were then passed to Cuffdiff, a tool which finds significant
changes in transcript expression. In Cuffdiff quartile normalization was
turned on, bias correction was set on, the minimum alignment count was set
to 10, and all other parameters were set to default. Both TopHat and Cuffdiff
were run on the free pubic Galaxy server (http://galaxyproject.org/). To
identify consistently deregulated genes, differential probes were identified
by the OK test in Cufflinks (Trapnell et al., 2010). Log ratios were calculated
as the difference between patient and control.
Quantification of CLOCK and MAT2A transcripts by real-time PCR
To validate the deregulated expression of CLOCK and MAT2A genes, we
enlarged our patient cohort. We analyzed 12 UCMD and nine Bethlem
myopathy, three patients with intermediate phenotypes and a pool made of
muscle controls. All ColVI patients have been clinically characterized with
regard to ‘circadian involvement’, date and time of biopsy, if the patients
were fasting or taking drugs, if the patients were ambulatory and the
presence of ventilation at the time of biopsy (Table S3). Total RNA was
isolated frommuscle sections using the RNeasy Kit (QIAGEN, Chatsworth,
CA) and reverse transcribed by using High Capacity cDNA Reverse
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Transcription Kit (Applied Biosystems). In order to quantify the steady
state level of CLOCK and MAT2A transcripts, commercially available
TaqMan expression assays (Applied Biosystems) were used (CLOCK:
Hs00231857_m1 NM_001267843 exon boundary 19–20; MAT2A:
Hs01553622_g1 NM_005911 exon boundary 5–6) as for β-actin as
housekeeping reference gene (ACTB Endogenous Control). Real-time
PCR was performed in triplicate on the Applied Biosystems Prism 7900HT
system, using 10 ng of cDNA and default parameters. Evaluation of
transcripts levels was performed by the comparative CT method (ΔΔCT
method). Statistical analysis was performed with a Student’s t-test.
Western blotting analysis in Col6a1−/− mice and ColVI patients
For immunoblotting analysis, frozen muscle tissues from both patients and
mice were ground in a dry-ice-cooled mortar and stored at −80°C. An
aliquot of each frozen muscle was suspended in lysis buffer (urea 7 M,
thiourea 2 M, CHAPS 4%, Tris-HCl 30 mM, and PMSF 1 mM) and
solubilized by sonication on ice. Samples were pooled and protein
concentrations were determined using PlusOne 2D-Quant kit (GE
Healthcare, Milan, Italy). Total protein extracts (50 µg) from pooled
Col6a1−/− (5 mice) and WT (5 mice) animal models, and from pooled
UCMD (4 patients), Bethlem myopathy (8 patients), 30 unrelated patients
with Duchenne (DMD) or Becker (BMD) muscular dystrophies, and
healthy control (5 subjects) muscles, were loaded in triplicate and
resolved on 14–8% gradient polyacrylamide gels. Blots were incubated
with rabbit polyclonal primary antibodies as follows: anti-MAT2A
(Novus Biologicals, NB110-94158; 1:1000), anti-CLOCK (Santa Cruz
Biotechnology, sc-25361; 1:500). After washing, the membranes were
incubated with anti-rabbit-IgG (GE Healthcare) secondary antibody
conjugated to horseradish peroxidase (1:5000). The signals were
visualized by chemiluminescence using the ECL Prime (GE Healthcare)
detection kit and the Image Quant LAS 4000 (GE Healthcare) analysis
system. Statistical analysis was performed applying the ANOVA and Tukey
tests (n=3, P<0.05).
Manipulations of Col6a1−/− animals, required for the experiments
described, conform to the rules of the Animal Experimental Commission
of the ‘Complesso Interdipartimentale A. Vallisneri, University of Padua
(Italy)’, where thework has been carried out. These regulations represent the
application of the D.L. 27/1/92 n. 116 of the Italian Government, which
meets Directive 86/609/EEC of the EUCouncil concerning the protection of
animals used for experiments and scientific purposes. The presented
procedures have been approved by the Animal Experimental Commission
with the certificate no. 22675.
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